# OnCo record paper-destiny-pantumor02-jco-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-destiny-pantumor02-jco-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-destiny-pantumor02-jco-2024" ;
  schema:name "DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours"@en ;
  schema:description "Across seven tumour types including endometrial, cervical and ovarian cancers, trastuzumab deruxtecan shrank tumours in about 37 percent of patients overall and 61 percent of those with the highest HER2 expression, leading to a tumour-agnostic approval."@en ;
  schema:url <https://onco.cc/key-papers/paper-destiny-pantumor02-jco-2024/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.23.02005>, <https://pubmed.ncbi.nlm.nih.gov/37870536/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.23.02005> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Meric-Bernstam F, Makker V, Oaknin A, et al." ;
  onco:cancers <https://onco.cc/cancers/endometrial-p53-abnormal/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>, <https://onco.cc/cancers/uterine-carcinosarcoma/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:trials <https://onco.cc/trials/destiny-pantumor02/> ;
  onco:journals <https://onco.cc/journals/jco/> .